Altimmune, Inc. (ALT)

Altimmune, Inc.'s stock has experienced volatility in the past six months, trending down by 2.17% and declining by 40.71% over the past year. In December 2025, the release of 48-week data from the IMPACT Phase 2b trial for pemvidutide in MASH led to a stock price drop, despite improvements in fibrosis measures. In January 2026, the FDA granted Breakthrough Therapy Designation for pemvidutide for MASH, resulting in a stock price increase. The company has consistently beaten analyst EPS forecasts in recent quarters.

As a clinical-stage biopharmaceutical company, Altimmune, Inc. does not have commercialized products generating revenue from sales, so traditional demand seasonality does not apply. The company's financial performance depends on the success of clinical trials and regulatory milestones, rather than seasonal fluctuations in product demand. The company's revenue is negligible, primarily stemming from non-core activities and interest income.

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing peptide-based therapeutics for obesity, metabolic, and liver diseases. Their primary product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist in Phase 3 trials for obesity and MASH. The company is also exploring pemvidutide for AUD and ALD. Historically, Altimmune has been involved in vaccine development, including influenza, hepatitis B, and anthrax vaccines.

Altimmune, Inc. is headquartered in Gaithersburg, Maryland, United States. The company has reported operations in China, Japan, the United Kingdom, Germany, and France.

Altimmune's brand reputation has been influenced by positive clinical advancements and market skepticism. The FDA's Breakthrough Therapy Designation for pemvidutide in MASH boosted the company's reputation. However, the market's negative reaction to the 48-week IMPACT Phase 2b trial data and bearish retail sentiment have impacted the reputation. A short report criticizing pemvidutide's competitiveness and tolerability also affected investor perception.

Individual investors hold the largest stake in Altimmune, Inc., with 59% of the shares. Institutional investors hold a substantial portion, with 295 owners holding 47,047,544 shares as of January 9, 2026. Major institutional shareholders include Vanguard Group Inc, BlackRock, Inc., and State Street Corp. Insider ownership is under 1%, although some individual insiders hold significant percentages of shares.